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LITTLE IS known about the influence of IL-2 on phagocytes.
We now describe the effects of human recombinant IL-2
on human neutrophil and monocyte functions related to
mobility, phagocytosis, glucose uptake, respiration and
degranulation. Neutrophil adherence and hexose mono-
phosphate shunt activities were both suppressed after
incubation with IL-2. IL-2 had no effect on neutrophil
migration, phagocytosis, deoxyglucose uptake or degranu-
lation, ionocytes demonstrated a greater sensitivity to
IL-2 with suppression ofmonocyte adherence, random and
stimulated migration, glucose uptake and hexose mono-
phosphate shunt activity, even after addition of phorbol
myristate acetate. Monocyte phagocytosis and degranula-
tion were not affected. All of the effects observed were
dose-dependent within a biologically active range for IL-2.
These studies suggest that IL-2 may have an important
down-regulatory role across a broad range of monocyte
functions including movement, deoxyglucose uptake and
respiration. However, its role in regulation of neutrophil
function is limited to adherence and respiration. IL-2 may
be a more versatile cytokine than has previously been
appreciated.
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Introduction
Interleukin-2 (IL-2) is a glycoprotein cytokine
with a broad range of immunoregulatory functions.
It has been shown to play a role in the
differentiation and proliferation of both B- and
T-lymphocytes by up- or down-regulation of
various subsets;
1-4 it can directly augment the
cytotoxic activity of natural killer cells and large
granular lymphocytes,
5-7 but may also indirectly
suppress this function, IL-2 has also been
implicated in monocyte/macrophage regulation as
these cells have been shown to bind IL-2 via specific
membrane receptors
9-11 and it has been shown to
enhance monocyte cytotoxic activity
2 and induce
macrophage resistance to infection.
13
The most widely studied of the membrane
receptors through which the IL-2 molecule
mediates its effects is the Tac protein, which is
expressed on primed or preactivated cells.
13 There
are, however, a number of other cell membrane
proteins on the surfaces of resting and stimulated
cells, which bind or are phosphorylated by IL-2.
4-6
While resting monocytes are devoid of the Tac
receptor protein, expression has been shown to
occur following culture with a number of classical
stimuli including lipopolysaccharide and interferon-
2.9 Addition of IL-2 to such stimulated ceils causes
an augmentation of microbicidal activity.9’1’12
Polymorphonuclear leukocytes have not been
demonstrated to display the Tac protein and,
consequently, possible modulation of their func-
tions by IL-2 has not been as extensively
investigated. Furthermore, neutrophils have only
recently been recognized as target cells for
immunoregulatory cytokines.7’8 In the light of
evidence that IL-2 modulates the activities of
various cell types via pathways other than the Tac
protein receptor,3’15’6 we set out to compare the
effect of IL-2 on two immunocyte subsets classically
devoid of Tac protein expression: the human
peripheral blood mononuclear phagocytes (mono-
cytes) and polymorphonuclear phagocytes (neu-
trophils).
Methods and Materials
Interleukin-2: Human recombinant IL-2 (AIa125)
from an Escherichia coli host was manufactured by
Amgen Biologicals, CA, USA and obtained
through Amersham International, UK, with a
specific activity of 2.6-2.8 103 unit//l. Purity
was at least 96% and lipopolysaccharide contamina-
tion was less than 0.09pg/ml at the highest
concentration of IL-2 used under the final assay
conditions. The alanine substitution for cysteine at
position 125 provides an increased specific activity
of up to 1 x 107 unit/mg protein in the T-cell
993 Rapid Communications of Oxford Ltd Mediators of Inflammation. Vol 2. 1993 59S. E. Smith et al.
growth assay and improves stability. Apart from
this, the biological properties of this product are
essentially indistinguishable from cell culture
derived material. One unit of activity is defined as
the amount of IL-2 which induces 50% of maximal
3H thymidine incorporation by IL-2 dependent
T-cells in culture (Amersham Product Technical
Information). A stock IL-2 solution of 1 000 U/ml
was prepared in 0.1% bovine serum albumin (BSA;
Sigma Chemical Co., St Louis, MO) in Dulbecco’s
phosphate buffered saline (DPBS; Flow Laborator-
ies, McLean, VA), and stored in aliquots at -70C
for up to 3 months. Concentrations of 2, 20 and
200 U/ml were used for these experiments since,
classically, 2-50 U/ml is required for the main-
tenance of IL-2 dependent T-cell lines.
Leukocyte preparation: Blood collected by vene-
puncture from healthy volunteer donors was
anticoagulated with heparin. The blood was layered
over Mono Poly Resolving Medium (Flow
Laboratories) and centrifuged at 400 x g for
30-40min. Neutrophils of 97% purity were
removed from the lower of the two leukocyte bands
formed at the interface.
19 The upper band,
containing mononuclear cells and platelets, was
enriched for monocytes using preformed contin-
uous density gradients made from Percoll (Pharma-
cia, South Seas) as described previously.
2 Briefly,
Percoll was aseptically made up to 325 mosM with
a density of 1.070 g/cm
3 with phosphate buffered
saline and 0.1% BSA; 10 ml of the solution was
spun at 21 000 x g in a Beckman Ultracentrifuge
(21C, fixed angle rotor) for 20min. The
mononuclear cell suspension, depleted of platelets
by centrifugation through autologous plasma, was
layered over the Percoll gradient and centrifuged at
1 000 x g for 15 min. The upper of the three bands
formed was collected using a hypodermic syringe
and needle and routinely yielded 70-90% mono-
cytes. The percentage of monocytes was assessed
using 0.01% Methylene Blue vital staining and the
accuracy of this method was periodically checked
with fluorescein-conjugated MO2 monoclonal anti-
body (Coulter Electronics, FL, USA) staining.
Leukocytes were washed twice and resuspended in
Medium 199 (M199; Commonwealth Serum
Laboratories, Australia) or in DPBS as dictated by
assay requirements.
Mobility assays: Adherence of leukocytes was
measured after passage through a dacron fibre
(100/.zg Olympic General Products, Queensland,
Australia) microcolumn as described previously.
21
Neutrophils were incubated with IL-2 for 30 min
prior to a 5 min contact with the fibre at 37C in a
humidified 5% CO2 atmosphere. Monocytes were
in contact with the fibre microcolumn for 30 min
in the presence of varying concentrations of IL-2.
Adherence was expressed as
Co C x 100%
Co
where Co is the original cell concentration and
Ce is the cell concentration in the effluent. All
monocyte suspensions were differentially stained to
exclude contaminant adherent lymphocytes from
the calculation. The under-agarose migration
assay
22 was used to measure random and stimulated
migration using autologous serum activated by
Candida albicans as the chemoattractant. IL-2 was
incorporated into 3 ml M199 and 10% FCS and 2%
agarose at the required concentrations. Triplicate
wells were punched 2.5 cm apart, once the agarose
had set in 60 mm diameter plastic tissue culture
plates. The centre well received the cell suspension,
the outer well received the chemoattractant (for
stimulated migration) and the inner well received
M199 (for random migration). Neutrophils were
allowed to migrate for 2.5 h at 37C in a humidified
CO2 atmosphere while monocytes required 18 h
incubation. The distance travelled towards either
well was measured with the aid of an eye piece grid
on an inverted microscope.
Phagocytosis assay: Phagocytosis was measured by the
inhibition of uridine uptake by C. albicans; once
phagocytosed, yeast cells do not incorporate
uridine.
23 Neutrophils or monocytes were pre-
incubated with IL-2 for 15 min in M199 and 2.5%
autologous serum. Live, washed C. albicans cells
were added and the mixture incubated for 30 min
at 37C with rotational mixing. Triplicate 0.1 ml
aliquots of the suspensions were dispersed in a
96-well microtitre tray and 5/ll 14C uridine (Amer-
sham) was added to achieve a final concentration of
0.93/.zCi/ml. This was incubated at 37C for 1 h,
centrifuged and measured for yeast uridine
incorporated (as loss of 14C from the supernatant)
by liquid scintillation counting (LSC). This value
was expressed as a proportion of the value obtained
for suspensions of yeast without leukocytes to give
a percentage of yeast phagocytosis.
Cell respiration assays: Glucose transport was assayed
indirectly by measuring the comparative concentra-
tions of 3H-2-deoxyglucose (3H-DOG; Amersham,
UK) in cell suspension supernatants, as described
previously.
24 Briefly, cells were incubated together
with varying concentrations of IL-2, in 96-well
round-bottom microtitre plates (Flow Laboratories)
to which 3H-DOG was added to give a final
concentration of 0.78/iCi/ml in a total of 0.2 ml
DPBS (Flow Laboratories). After allowing uptake
for 30 or 60min at 37C for neutrophils and
monocytes, respectively, the plates were centrifuged
at 800 x g for 5 min and 0.05 ml of supernatant was
removed for LSC. Uptake of 3H-DOG was
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calculated as the total disintegration/ml added
minus the disintegration/ml remaining in the
supernatant. A standard assay for hexose mono-
phosphate shunt (HMPS) activity which measures
the conversion of D-(1-14C) glucose (Amersham)
2s
to 14CO2 in the oxidative pathway of energy
generation, was adapted to microassay form using
two tube caps in small sealed jars. In one of the
caps, 0.4 ml cell suspensions in DPBS containing
varying concentrations of IL-2 and 14C glucose at
a final concentration of 0.25 #Ci/ml were incubated
at 37C for 45 min. Then 1 M hydrochloric acid was
added to drive out dissolved 14CO. which was
captured in 0.2 ml 5 M sodium hydroxide contained
in the second cap and quantitated by LSC. Phorbol
myristate acetate (PMA, Sigma) was added in some
experiments after preliminary incubation of cells
with IL-2 for 30 min.
Degranulation assays: A standard optical density assay
for lysozyme activity based on lysis of dried
Micrococcus lysodeiktius (Sigma reagents) was used to
gauge specific granule release in the cell super-
natants. Cells were incubated in 96-well microtitre
plates with IL-2 in DPBS and 1% glucose for 30 min
at 37C.
26 Beta-glucuronidase activity was used as
a marker for azurophilic granule release in
supernatants as for lysozyme activity and was
assayed spectrophotometrically using phenolphtha-
lein-glucuronic acid substrate (Sigma).
26 For both
assays data is represented as a percentage of total
cell enzyme content determined from sonicated
suspensions. In some experiments the calcium
ionophore A23187 (calimycin, 7.5 mM; Sigma) was
added after cells were preincubated with IL-2 for
30 min.
Statistical anasis" All experimental data are re-
presentative of two to five similar experiments
performed in triplicate with individual standard
deviations (SD) of less than 10%. Values are
expressed as mean _-t- SD and statistical significance
was measured with the Student’s t-test.
Results
Mobility: Adherence of both neutrophils and
monocytes to dacron fibre was decreased following
incubation with IL-2 (Fig. 1). The efl:ect on
migration under agarose differed for the two
phagocyte types: neither neutrophil random nor
stimulated migration was altered as a result of
exposure to IL-2, while both monocyte random and
stimulated migration decreased significantly with
increasing concentrations of IL-2 (Fig. 2(a) and (b)).
Chemotactic indices for the monocytes were
calculated from the ratio of stimulated mi-
gration/random migration. The indices for the
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FIG. 1. Phagocyte adherence to dacron fibre decreased with increasing
IL-2 concentrations. Final cell concentration was 5 106 ml. Neutrophils
(0) and monocytes (O) both demonstrate decreased adherence at
200 U/ml IL-2. p < 0.01, p < 0.02.
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FIG. 2. (a) random and (b) stimulated migration under agarose of
neutrophils (0) and monocytes ((C)) treated with IL-2. (Data for (a) and
(b) were collected from the same experiments.) Monocyte random and
stimulated migration decreased with increasing L-2 concentrations while
neutrophil migration remained unaffected. p < 0.001, p < 0.01.
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Table 1. Concentrations of L-2 between 2 and
200 U/ml had no effect on neutrophil or
monocyte phagocytosis
[IL-2] Neutrophils
U/ml (%)
Monocytes
(%)
48.8 + 4.8
50.0 _+ 8.9
49.0 _+ 6.6
49.8 _+ 7.3
0 43.8 + 4.4
2 45.5 ___
5.2
20 46.5 + 6.3
200 42.8 ___
6.1
various concentrations of IL-2 did not vary
significantly from that of the control, being
1.30 _-4- 0.07 for the control and 1.37 0.09,
1.29 q- 0.03 and 1.29 _-4- 0.14 for 2, 20 and 200 U/ml,
respectively.
Phagocytosis: Typically, under our conditions, the
phagocytosis assay yielded 40-50% uptake of C.
albicans over a 30 min incubation period, neu-
trophils demonstrated no response to IL-2 in this
assay and monocyte phagocytosis remained simi-
larly unaffected (Table 1).
Respiration: Figure 3 demonstrates that IL-2 at
concentrations of 2, 20 and 200U/ml did not
significantly affect 3H-DOG uptake of resting
neutrophils. In contrast, monocytes showed a
significant decrease in transport of deoxyglucose at
a concentration of 200 U/ml of IL-2 ( < 0.01) with
individual experiments indicating significant sup-
pression at concentrations as low as 2 U/ml (data
not shown). HMPS activity was significantly
depressed for neutrophils at concentrations of 20
and 200 U/ml and for monocytes at concentrations
of 2, 20 and 200 U/ml (Fig. 4(a)). Stimulation with
PMA at 0.1/g/ml enhanced HMPS activity of both
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FIG. 4. (a) Effect of increasing IL-2 concentrations reduced both
neutrophil (0) and monocyte (O) hexose monophosphate shunt
activity. Final cell concentrations were x 106neutrophil/ml and
5 x 105monocyte/ml. **p_<0.001, *p<0.01, Tp_<0.05. (b) Mono-
cytes preincubated with IL-2 at 200 U/ml for 30 min displayed reduced
HMPS activity even after stimulation by PMA. Neutrophils no longer
showed a significant response to IL-2 after stimulation by PMA. The
control indicates the uptake of cells which did not have IL-2 added, but
were otherwise treated similarly to the IL-2 test suspensions.
Experimental conditions were as for (a). Statistical comparisons were
made between the control/PMA control (I-]) and the respective IL-2 test
(11) activity, i.e. adjacent bars. p _< 0.01, p < 0.001.
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FIG. 3. Effect of increasing IL-2 concentrations on 3H-deoxyglucose
transport. Monocyte ((C)) activity was reduced at 200 U/ml, neutrophil
(0) activity was unaffected. Final cell concentrations were 2 x 106
neutrophil/ml and x 106monocyte/ml; 3H-DOG concentration was
0.78/Ci/ml. p < 0.01.
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cells. Addition of PMA (0.1/,zg/ml) to neutrophils
elicited an equivalent stimulated response in both
control cells (no IL-2 preincubation) and those
preincubated with 1L-2 at 200 U/ml. However, the
addition of PMA to monocytes which had been
preincubated with IL-2 induced a response
significantly less than that in control monocytes
(Fig. 4(b)).
Degranulation: Specific granule release was not
significantly affected by incubation of neutrophils
or monocytes with any concentration of IL-2
assessed. Similarly, azurophilic granule release did
not vary significantly from the control for resting
or stimulated phagocytes (Table 2(a) and (b)).
Table 3 summarizes the observed effects of IL-2
on neutrophil and monocyte function.
Deactivated IL-2" IL-2 at a concentration of 200 U/ml
was compared with IL-2 that had been heated to
80C for 1 h and similarly diluted. The suppressionSuppression ofphagocytes by IL-2
Table 2. (a) Effect of IL-2 on neutrophil and monocyte azurophilic granule releasea. (b) Effect of IL-2 on neutrophil and
monocyte specific granule release with and without simulation by addition of calcium ionophore A23187
b
(a) (b)
[I L-2 Neutrop hi Is Monocytes 623178 [I L-2] Neutrophils Monocytes
0(U/ml) 28.2 + 1.3 12.9 _+ 3.5
2 28.7 2.0 12.3 _+ 4.8
[20] 25.8 + 2.1 11.5 _+ 4.7
[200] 27.4 + 1.2 12.3 _+ 5.7
-[0] 4.7 _+ 1.5 5.2 -I-0.6
-[2] 4.1 _+ 0.8 4.9 _+ 0.8
-20 4.4 ___
0.8 4.8 -t- 0.4
-[200] 5.0 _+ 0.6 5.1 _+ 0.4
+ [0] 14.9 _+ 4.1 20.3 _+ 13.1
+ [2] 14.1 _+ 2.8 18.3 _+ 9.5
+20 14.2 ___
3.4 17.7 _+ 10.9
+[200] 16.6 _+ 6.1 19.3 _+ 10.2
Results expressed as per cent of total fl-glucuronidase content.
Results expressed as per cent of total lysozyme count.
Table 3. Summary of assay results" effects of L-2 on neutrophil
and monocyte activities
Neutrophils Monocytes
Adherence (Fig. Suppressed Suppressed
Migration (Fig. 2) Suppressed
Phagocytosis (Table
Deoxyglucose uptake (Fig. 3) Suppressed
HMP shunt (Fig. 4) Suppressed Suppressed
Degranulation (Table 2)
of neutrophil HMPS activity and adherence by IL-2
was significantly reduced, but not totally abrog-
ated by heating. Heat treatment also significantly
reversed the suppressive effect of IL-2 on monocyte
HMPS activity. The suppressive effect on monocyte
migration was totally abrogated by heat treatment
of IL-2. Similarly, expired IL-2 (stored at 4C for
at least 6 months) was no longer able to vary
monocyte and neutrophil adherence values from
that of control M199 (data not shown).
Discussion
Under our in vitro conditions we have shown that
recombinant IL-2 exerts a suppressive effect on
selected functions of freshly isolated resting and
stimulated phagocytic cells. As summarized in
Table 3, neutrophil adherence was reduced while
migration and phagocytosis were not. Hexose
monophosphate shunt activity was reduced by IL-2,
however, stimulation of the cells with PMA negated
this effect. Glucose uptake and cytoplasmic granule
release were not aected. Compared to neutrophils,
monocyte sensitivity to IL-2 was more pronounced
with both a larger number of functions being
affected and more profoundly so. Monocyte
adherence and migration were reduced as were
glucose uptake and HMP shunt activity. Phagocyt-
osis and granule release were not affected.
The greater diversity of monocyte functions
affected by IL-2 as compared to neutrophils may
not be surprising since IL-2 is classically a cytokine
of the lymphoid mononuclear cell line, with which
monocytes are known to interact closely in various
phases of the immune response. However, the
activity of IL-2 is not restricted to these cells and
its eects may be diverse, for example, IL-2 is able
to stimulate the release of prostacyclin by
endothelial cells,
27 so again it is not unexpected that
neutrophils could also be targeted.
The more profound effect of IL-2 on monocytes
than on neutrophils was noticed particularly at the
respiratory level. Membrane transport of deoxy-
glucose, a non-metabolizable glucose analogue and
HMP shunt activity were both reduced in
monocytes. The decreased availability of in-
tracellular glucose correlates with the decreased
activity state of the cell. As demonstrated by the
migration assays, monocyte kinetic energy was
reduced. The monocyte chemotactic indices (che-
motaxis:random migration) for different IL-2
concentrations did not vary significantly, indicating
that IL-2 did not affect the cells’ ability to detect
and respond to a chemotactic gradient. However,
both random migration and chemotaxis values were
reduced, indicating a slower response and decreased
cell kinetic energy level. In contrast, neutrophil
HMP shunt activity, but not deoxyglucose uptake,
was suppressed by IL-2. Thus, glucose may have
still been available via other respiratory pathways
to support more of the neutrophils’ activities.
We observed that the effect of IL-2 was not
globally suppressive, but was restricted to certain
areas of cell functions as has been previously noted
by others. Kennedy et al. found that IL-2
suppressed T-helper cell activation, but not
T-helper cell effector function (i.e. T-helper
cell-B-cell cooperation). Jablons et al.
28 and
Klempner et al.
29 both reported that in vivo IL-2
administration resulted in depression of only some
neutrophil cell functions related to host defence
against bacterial infections. Jablons found neu-
trophil chemotaxis to be decreased together with
superoxide production and FcJ 111 expression,
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while phagocytosis and antibody-dependent cellular
cytoxicity were minimally affected.
28 Klempner
et al.29 also observed suppression of neutrophil
chemotaxis, but found that other functions,
including superoxide production were not de-
creased. Kowanko and Ferrante3 have also
demonstrated suppression of neutrophil migration,
but stimulation of the respiratory burst and
degranulation.
The contradictory effects observed by others and
ourselves may be due to differences in the state of
priming or deactivation of neutrophils under
different study conditions.
31 Freshly harvested cells
from normal donors may not be fully dormant if
they have been exposed to even ’trivial’ quantities
of endotoxin or have been triggered by adherence
to surfaces during preparation.
2 Inconsistencies in
the reported effects of IL-2 may indicate that the
modulatory effects of IL-2 on neutrophils are highly
sensitive to the state of activation of the target cell
and to the interaction of other mediators. This may
be the explanation for our observation that HMP
shunt activity is significantly reduced by IL-2 in
resting neutrophils, but not in PMA stimulated
neutrophils. Similarly the state of activation of the
monocyte may alter the observed effects of IL-2.
Hellstrand and Hermodsson found that IL-2
induced suppression of natural killer cell cytotoxi-
city occurs indirectly via a p55IL-2R locus on
monocytes. They showed that the primary
IL-2-monocyte interaction leading to killer cell
suppression could only occur in monocytes prior to
adherence, demonstrating the importance of the
activation state.
The variation in the observed effects of IL-2 on
neutrophil chemotaxis may also be due to the
different sources of IL-2 or its purity. The IL-2
Ala125 product used in this study is a recombinant
molecule which contains an extra methionine
residue at the N-terminus of the natural sequence
molecule. This addition has had no demonstrable
effect on the classic biological activity of the
molecule as determined by various cell culture assay
systems. The cysteine residue at position 125 has
also been substituted by alanine which has resulted
in a five-fold increase in specific activity as well as
improving stability (Amersham Technical Informa-
tion). Preliminary experiments comparing purified
rat IL-2 with the Amersham product demonstrated
a similar effect on neutrophil adherence (data not
shown). However, the possibility remains that this
difference in structure may affect the neutrophil
response in the chemotaxis assay.
The effects of IL-2 on neutrophils and monocytes
that we observed were consistently suppressive.
Although IL-2 first became recognized because of
its requirement for T-cell proliferation and, more
recently, augmentation of cytotoxicity in natural
killer cells and macrophages,
s-9 it has been shown
to exert several down-regulatory effects, e.g.
myelopoiesis, specifically granulocyte-macrophage
colony formation’4 and T-helper cell activation. 1’4
It is unclear whether the suppressive effect of IL-2
on the myelopoietic progenitor cell is mediated via
regulatory T-cells
3 or acts directly.
4 It would seem
logical that any direct effect of IL-2 on the product
of the myelopoietic progenitor cell, i.e. the
circulating neutrophil and monocyte, may also be
correspondingly suppressive under similar condi-
tions. An indirect T-cell mediated effect is unlikely
in our neutrophil experiments as the total
lymphocyte contamination was only 1-2%. Burdach
et al. did observe a T-cell mediated effect, but their
T-cell versus effector cell ratio was 1:5. The short
assay incubation times also favour a direct effect.
However, contamination of the monocyte prepara-
tion by lymphocytes ranged from 10 to 30%, which
may have allowed interaction with T-cells. The
assay times again favoured a direct effect in all, but
the random migration and chemotaxis experiments.
Once cells migrate into tissue compartments their
activation state and response may be altered,
depending on the presence of other cytokines and
activators. Thus, Wahl et al.
9 found that IL-2
augmented monocyte microbicidal activity, but
only after the monocytes had been activated and
cultured to express the IL-2 Tac receptor. The
appearance of these receptors on the cells during
the process of macrophage maturation occurs as the
ceils become localized in the tissues. Hall et al. 27
also suggested that IL-2 may regulate the inductive
phase of the immune response by inhibiting the
proliferative response of T-cells to mitogens and
preventing further attachment of leukocytes via
stimulation of prostacyclin production by en-
dothelial cells, which may be another indirect
down-regulatory effect on circulating phagocytes.
Modulation of leukocyte function by IL-2 has
been demonstrated to operate via the Tac protein
which was, until recently, believed to be expressed
only by activated T-cells. Experimental evidence
has extended the modulatory role of IL-2 to include
a much wider range of cells as mentioned
previously. More recently, cell membrane proteins
distinct from the Tac receptor protein have been
found which bind IL-2 and cause activation in ceils
including natural killer cells and’ certain B-cell
lines.s Thus, as freshly isolated peripheral blood
monocytes and neutrophils do not possess the Tac
IL-2 receptor protein,
l an interaction with IL-2 via
other membrane receptors is probable. Our findings
support this, as the only assays we used which allow
suflqcient time for new Tac protein synthesis and
expression were the monocyte random migration
and chemotaxis assays.
We are confident that the effects we describe here
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are due to the activity of IL-2. We have previously
demonstrated that endotoxin is unlikely to be
implicated as Polymyxin B does not affect these
assays
21 and the effects are depressive rather than
stimulatory which would be expected of endotoxin.
Furthermore, we have shown the activity to be
sensitive to heat, which endotoxin is not and to fade
after prolonged storage. Interestingly, the effect of
IL-2 was not totally abrogated by heating as
measured by the HMP shunt and adherence assays.
This is consistent with the observation that the
Ala125 residue substitution in our IL-2 preparation
increases heat stability of the recombinant molecule
over that of purified IL-2 (Amersham Technical
Information). Heating of this preparation to 80C
for 24 h at the production laboratories demon-
strated retention of up to 25% of original biological
activity as measured by standard assay (personal
communication with Amersham Technical Advi-
sor). After 6 months storage at 4C, IL-2 activity
was totally lost as measured in the monocyte and
neutrophil chemotaxis assay (data not shown).
Finally, the effects observed occurred over a
concentration range similar to that shown to have
biological effects on other cells.
Our data supports the view that IL-2 is a
multifunctional cytokine which influences a variety
of immune cells and activities probably depending
on the hosts’ current immune state and the local
tissue milieu.
References
1. Kennedy M, Wassmer P, Erb P. A novel role for interleukin-2 in antibody
responses down-regulation of T-helper cell activation. J Immuno11987 139:
110-113.
2. Hammer SM, Gillis JM. Effects of recombinant interleukin-2 resting
human T-lymphocytes. J Biol Response Mod 1989; S: 3644.
3. Bich-Thuy LT, Fauci AS. Direct effect of interleukin-2 the
differentiation of human B-cells which have not been preactivated in vitro.
Eur J Immunol 1985; 15: 1075--1079.
4. Otten G, Herold KC, Fitch FW.. Interleukin-2 inhibits antigen-stimulated
lymphokine synthesis in helper T-cells by inhibiting calcium-dependent
signalling. J Immuno11987 139: 1348--1353.
5. Hoyer M, Meineke T, 1,ewis W, Zwilling B, Rinehart J. Characterization
and modulation of human lymphokine (interleukin-2) activated killer cell
induction. Cancer Res 1986; 46: 2834-2838.
6. Lattime EC, Bykowsky MJ, Stutman O. Natural cytotoxic (NC) activity:
multi-lineage system regulated by interleukin-2. Immunol Res 1986; 5: 5-15.
7. Zhang SR, Salup RR, Urias PE, Twilley TA, Talmadge JE, Herberman RB.
Augmentation of NK activity and/or macrophage mediated cytotoxicity in
the liver by biological response modifiers including human recombinant
interleukin-2. Cancer Immunol Immunother 1986; 21: 19--25.
8. Hellstrand K, Hermodsson S. Interleukin-2 induce suppression of human
natural killer cell cytotoxicity. Clin Exp Immunol 1989; 79: 410-416.
9. Wahl SM, McCartney-Francis N, Hunt DA, Smith PD, Wahl I,M, Katona
IM. Monocyte interleukin-2 receptor gene expression and interleukin-2
augmentation of microbicidal activity. J Immunol 1987 139: 1342-1347.
10. Herrmann F, Cannistra SA, I,evine H, Griffin JD. Expression of
interleukin-2 receptors and binding of interleukin-2 by gamma interferon-
induced human leukemic and normal monocytic cells. J Exp Med 1985; 162:
1111-1116.
11. Hancock WW, Muller WA, Contran RS. Interleukin-2 receptors
expressed by alveolar macrophages during pulmonary sarcoidosis and
inducible by lymphokine treatment of normal human lung macrophages,
blood monocytes, and monocyte cell lines. J Immuno11987; 138: 185-191.
12. Malkovsky M, Loveland B, North M, Asherson GL, Gao L, Ward P, Fiers
W. Recombinant interleukin-2 directly augments the cytotoxicity of human
monocytes. Nature 1987; 325: 262-265.
13. Belosevic M, Nacy CA. IL-2, anti-IL-2 receptor antibody and activation of
macrophages. Cell Immunol 1990; 128: 635-640.
14. Gaulton GN, Eardley DD. Interleukin-2-dependent phosphorylation of
interleukin-2 receptors and other T-cell membrane proteins. J Immuno11986;
136: 2470-2477.
15. Robb Rj, Rusk CM, Yodoi J, Greene WC. Interleukin-2 binding protein
distinct from the Tac protein: analysis of its role in formation of high-affinity
receptors. Proc NatlM cad Sd USM 1987; 84: 2002-2006.
16. Bich-Thuy LT, Dukovich M, Peffer NJ, Nauci AS, Kehrl JH, Greene
WC. Direct activation of human resting T-cells by IL2: the role of IL2
receptor distinct from the Tac protein. J Imm#no11987; 139: 1550-1556.
17. Campbell PA. The neutrophil, professional killer of bacteria, may be
controlled by T-cells. Clin Exp Immunol 1990; 79: 141-143.
18. Dinarello CA. The pro-inflammatory cytokines interleukin-1 and TNF
and treatment of the septic shock syndrome. J Infect Diseases 1991; 163:
1177-1184.
19. Ferrante A, Thong YH. Optimal conditions for the simultaneous purification
of mononuclear and polymorphonuclear phagocytes from human blood. J
Immunol Methods 1980; 36: 109-117.
20. Gmeylig-Meyling R, Waldermann TA. Separation of human blood
monocytes and lymphocytes continuous percoll gradient. J Immunol
Methods 1980; 33: 1-9.
21. Thong YH, Currell JM. Development of microassay technique for
neutrophil adherence. J Immunol Methods 1983; 63: 22%236.
22. Ferrante A, Beard J, Thong YH. Early decay of human neutrophil
responsiveness following isolation from peripheral blood. Clin Exp Immunol
1980; 39: 532-537.
23. Yamamura M, Boler J, Valdimarsson H. Phagocytosis measured inhibition
of uridine uptake by Candida albicans. J Immunol Methods 1977; 19: 10-15.
24. Seow WK, Thong YH, McCormack JG, Ferrante A. Lymphokine-
neutrophil interactions: opposite effects of interleukin-2 and tumour necrosis
factor-beta (lymphotoxin) human neutrophil adherence. Int Arch Allergy
Appl Immunol 1988; 85: 63-68.
25. Ferrante A, Rencis VO. Enhancement of base hexose-monophosphate shunt
activity of human polymorphonuclear leukocytes by human y-interferon.
Immunol Lett 1989; 8: 215-217.
26. Metcalf JA, Gallin JI, Nauseef WM, Root RK. Laboratory Manual of
Neutrophil Function. New York: Raven Press, 1986; 147-148.
27. Hall ER, Papp AC, Seifert WE, Jr, Wu KK. Stimulation of endothelial cell
prostacyclin formation by interleukin-2. Lymphokine Res 1986; 5: 87-96.
28. Jablons D, Bolton E, Mertins S, Rubin M, Pizzo P, Rosenberg SA, Lotze
M. Interleukin-2 based immunotherapy alters circulating neutrophil Fc
receptor expression and chemotaxis. J Immuno11990; 144: 3630-3636.
29. Klempner MS, Noring R, Mier JW, Atkins MB. An acquired chemotactic
defect in neutrophils from patients receiving interleukin-2 therapy. N Engl
J Med 1990; 322: 959-965.
30. Kowanko IC, Ferrante A. Interleukin-2 inhibits migration and stimulates
respiratory burst and degranulation of human neutrophils in vitro. Immunol
Lett 1987; 15 285-289.
31. Tauber AI, Karnad AB, Hartshorn KL, Myers JB, Smartz JH. Parameters
of neutrophil activation: models of priming and deactivation. Biochem Acute
Allergic Reactions: Fifth Int Syrup. Alan R Liss, Inc., 1989; 297-309.
32. I,ord R. Assessment of neutrophil function. Med Lab Sci 1989; 46: 347-356.
33. Burdach S, Shatsky M, Wagenhorst B, Levitt L. Receptor specific modulation
of myelopoiesis by recombinant DNA-derived interleukin-2. J lmmuno11987;
139: 452-458.
34. Naldini A, Fleischmann WR, Zuhair JR, Ballas K, Klimpel KD, Klimpel
GR. Interleukin-2 inhibits in vitro granulocyte-macrophage colony
formation. J Immunol 1987; 139: 1880-1884.
ACKNOWLEDGEMENTS. We wish to thank the Mater Public Hospital
Immunology Laboratory for the monoclonal antibody staining and monocyte
enumeration of mononuclear cell suspensions. Funding for ’this work
provided by the J. p. Kelly Mater Research Fund and the Mayne Bequest Fund,
University of Queensland. We also thank Mary Herwig for the typing of this
manuscript.
Received 3 November 1992"
accepted in revised form 7 December 1992
Mediators of Inflammation. Vol 2.1993 65